Edition:
India

Evotec SE (EVTG.DE)

EVTG.DE on Xetra

19.79EUR
9:05pm IST
Change (% chg)

€-0.12 (-0.63%)
Prev Close
€19.92
Open
€19.88
Day's High
€20.24
Day's Low
€19.57
Volume
1,339,956
Avg. Vol
1,176,258
52-wk High
€27.29
52-wk Low
€15.44

Latest Key Developments (Source: Significant Developments)

Evotec Lifts Guidance, Sees F-Y Operating Profit Rising by Over 10% After H1
Wednesday, 14 Aug 2019 

Aug 14 (Reuters) - Evotec SE ::H1 REVENUE ROSE 16 PERCENT TO 207.1 MILLION EUR.DGAP-NEWS: EVOTEC SE REPORTS FIRST HALF-YEAR 2019 RESULTS AND CORPORATE UPDATES.STRONG OUTLOOK FOR YEAR - GUIDANCE INCREASED.STRONG FIRST HALF YEAR WITH 16% INCREASE IN GROUP REVENUES, 51% EBITDA.GROUP REVENUES UP 16% TO EUR 207.1 M (H1 2018: EUR 178.9 M).ADJUSTED GROUP EBITDA UP 51% TO EUR 58.2 M (H1 2018: EUR 38.6 M).UNPARTNERED RESEARCH AND DEVELOPMENT EXPENSES OF EUR 18.7 M (H1 2018: EUR 10.0 M).GROUP REVENUES FROM CONTRACTS WITH CUSTOMERS WITHOUT REVENUES FROM RECHARGES ARE EXPECTED TO INCREASE BY APPROX. 15% (PREVIOUSLY: APPROX. 10%) (2018: EUR 364.0 M).ADJUSTED GROUP EBITDA IS EXPECTED TO INCREASE BY >10% (PREVIOUSLY: APPROX. 10%) (2018: EUR 92.0 M).GUIDANCE ON UNPARTNERED RESEARCH AND DEVELOPMENT EXPENSES REMAINS UNCHANGED AT EUR 30-40 M (2018: EUR 22.9 M).  Full Article

Evotec And Lygature In Cooperation To Develop Antibacterial Agents
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - EVOTEC SE ::EVOTEC SE AND LYGATURE ANNOUNCED COOPERATION FOR DEVELOPMENT OF ANTIBACTERIAL AGENTS.TO DO 3 PROGRAMS, 1 TO COMPLETE PHASE I STUDIES, 1 TO INVESTIGATIONAL NEW DRUG (IND) STAGE AND/OR UP TO 2 REACHING CLINICAL DEVELOPMENT CANDIDATE STAGE, BY 2024.IMI, WORLD'S LARGEST PUBLIC-PRIVATE PARTNERSHIP (PPP) IN LIFE SCIENCES, WILL MATCH EVOTEC'S IN-KIND CONTRIBUTION WITH A EUR 12 M GRANT OVER NEXT SIX YEARS.  Full Article

Evotec SE Acquires Assets From Stem Cell Specialist Ncardia AG
Monday, 15 Jul 2019 

July 15 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC EXPANDS ITS IPSC DISCOVERY PLATFORM.ACQUIRED ASSETS FROM NCARDIA AG INCLUDE IP PORTFOLIO, IPSC-BASED CELLULAR PRODUCTS AND AN EXPERIENCED STEM CELL BIOLOGY TEAM.ACQUIRED ASSETS INCLUDE INTELLECTUAL PROPERTY RELEVANT FOR IPSC-BASED PHENOTYPIC DRUG DISCOVERY, AN EXISTING CELLULAR PRODUCT BUSINESS AROUND IPSC-DERIVED CELLS, AS WELL AS 17 STRONG TEAM OF STEM CELL BIOLOGY EXPERTS OPERATING FROM LABORATORIES AT BIOCAMPUS COLOGNE.  Full Article

Evotec, Sensyne Health And Oxford University In Bridge Partnership LAB10x
Monday, 24 Jun 2019 

June 24 (Reuters) - EVOTEC SE ::EVOTEC, SENSYNE HEALTH, THE UNIVERSITY OF OXFORD, OSI, AND OUI CREATE NEW BRIDGE PARTNERSHIP 'LAB10X' IN DIGITAL HEALTH.TOGETHER WITH SENSYNE HEALTH PLC, OXFORD UNIVERSITY INNOVATION LTD AND OXFORD SCIENCES INNOVATION WILL FUND EVOTEC'S NEW BRIDGE LAB10X.AIM OF THIS BRIDGE IS TO RAPIDLY TRANSLATE OXFORD'S CLINICAL AI AND DIGITAL HEALTH RESEARCH INTO BUSINESS SPIN-OFFS.UNDER THE AGREEMENT, OUI DIGITAL HEALTH PROJECTS WILL BE ACCEPTED EXCLUSIVELY BY OXFORD UNIVERSITY SCIENTISTS AND SUPPORTED BY EXPERT FROM SENSYNE.LAB10X IS FUNDED BY A FUND THAT WILL INITIALLY COST AROUND £ 5M (APPROXIMATELY € 5.6M) FOR THREE YEARS..TECHNOLOGIES DEVELOPED IN LAB10X-BRIDGE WILL BE USED TO GENERATE AND EVALUATE ANONYMISED PATIENT DATA.  Full Article

Evotec Confirms Guidance For 2019
Tuesday, 14 May 2019 

May 14 (Reuters) - Evotec SE ::EVOTEC SAYS OPERATING RESULT AMOUNTED TO EUR 19.1 M IN Q1 2019.EVOTEC SAYS FINANCIAL GUIDANCE 2019 CONFIRMED.Q1 REVENUE ROSE 27 PERCENT TO 103.8 MILLION EUR.  Full Article

Evotec, Almirall Enter Into Research Collaboration
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Evotec AG ::EVOTEC AND ALMIRALL ENTER INTO RESEARCH COLLABORATION IN THE FIELD OF DERMATOLOGICAL DISEASES.WILL RECEIVE RESEARCH FUNDING AND MAY BE ELIGIBLE TO RECEIVE DISCOVERY, PRE-CLINICAL, CLINICAL AND SALES MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES.  Full Article

Evotec, Celgene Partner On Targeted Protein Degradation
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC AND CELGENE ENTER PARTNERSHIP IN THE FIELD OF TARGETED PROTEIN DEGRADATION.SAYS FINANCIALS INCLUDE UPFRONT PAYMENT AS WELL AS SIGNIFICANT POTENTIAL MILESTONE-BASED PAYMENTS AND ROYALTIE.  Full Article

Evotec To Integrate Sanofi's Infectious Diseases Unit
Monday, 18 Jun 2018 

June 18 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC AND SANOFI SIGN DEFINITIVE AGREEMENT TO COMBAT INFECTIOUS DISEASES.100 EMPLOYEES WILL JOIN EVOTEC.SANOFI TO PROVIDE SIGNIFICANT SUPPORT TO EVOTEC INCLUDING A ONE-TIME, UPFRONT PAYMENT OF EUR 60 M.SANOFI WILL RETAIN CERTAIN OPTION RIGHTS ON DEVELOPMENT, MANUFACTURING AND COMMERCIALISATION OF ANTI-INFECTIVE PRODUCTS RESULTING FROM LICENSED ASSETS.TRANSACTION WILL RESULT IN INCREASED OPERATING INCOME AS WELL AS INCREASED RESEARCH AND DEVELOPMENT EXPENDITURE.TRANSACTION WILL BE SLIGHTLY ACCRETIVE TO EVOTEC'S EBITDA FOR NEXT FIVE YEARS.  Full Article

I'rom Group unit concludes iPS cell generation technology licensing agreement with Evotec International GmbH
Wednesday, 16 May 2018 

May 16 (Reuters) - I'rom Group Co Ltd <2372.T>:Says its unit ID Pharma Co., Ltd. concluded an iPS cell generation technology related licensing agreement with Germany company Evotec International GmbH .Says its unit will receive upfront payment and annual royalty from Evotec International GmbH .  Full Article

Evotec, Apeiron Biologics receive milestone payment from Sanofi
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Evotec Ag ::SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​.SAYS ‍MILESTONE PAYMENT OF EUR 3 M WILL BE SPLIT EQUALLY BETWEEN TWO BIOTECH COMPANIES​.SAYS ‍SUCCESS PAYMENT WAS TRIGGERED WHEN PARTNERS SUCCESSFULLY ADVANCED AN UNDISCLOSED, NOVEL IMMUNO-ONCOLOGY SMALL MOLECULE INTO LATE-STAGE PRE-CLINICAL DEVELOPMENT​.SAYS ‍UNDER ALLIANCE, THREE COMPANIES WORK TOGETHER TO IDENTIFY SMALL MOLECULE LEADS AND TARGETS FOR NEXT-GENERATION THERAPIES IN IMMUNO-ONCOLOGY​.  Full Article